Monique Hinchcliff, MD, MS

• Albert Sinusas
• Aldo Peixoto
• Attila Feher
• Bauer Sumpio
• Dana Peters
• Danielle Antin-Ozerkis
• Dennis G Moledina
• Edward J Miller
• Erica Herzog
• F. Perry Wilson
• Hongyu Zhao
• Ian Odell
• Jeffrey Testani
• Naftali Kaminski
• Richard Flavell
• Shawn Cowper
• Sherry Mansour
• Stephanie Thorn
• Yi-Hwa Liu
• Yuval Kluger

Artificial Intelligence; Pulmonary Fibrosis; Raynaud Disease; Scleroderma, Localized; Scleroderma, Systemic; Scleroderma, Diffuse; Scleroderma, Limited; Microvascular Rarefaction

• Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung diseaseYang M, Lee S, Neely J, Hinchcliff M, Wolters P, Sirota M. Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease. Frontiers In Immunology 2024, 15: 1326922. PMID: 38348044, PMCID: PMC10859856, DOI: 10.3389/fimmu.2024.1326922.
• IL-6 trans-signaling in a humanized mouse model of sclerodermaOdell I, Agrawal K, Sefik E, Odell A, Caves E, Kirkiles-Smith N, Horsley V, Hinchcliff M, Pober J, Kluger Y, Flavell R. IL-6 trans-signaling in a humanized mouse model of scleroderma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2306965120. PMID: 37669366, PMCID: PMC10500188, DOI: 10.1073/pnas.2306965120.
• Prognostic significance of pericardial effusion in systemic sclerosis-associated pulmonary hypertension: analysis from the PHAROS Registry.Luo Y, Gordon J, Xu J, Kolstad K, Chung L, Steen V, Bernstein E, Csuka M, Derk C, Domsic R, Fischer A, Frech T, Goldberg A, Hant F, Hinchcliff M, Horn E, Hummers L, Hsu V, Kafaja S, Khanna D, Molitor J, Saketkoo L, Shapiro L, Silver R, Simms R. Prognostic significance of pericardial effusion in systemic sclerosis-associated pulmonary hypertension: analysis from the PHAROS Registry. Rheumatology 2023 PMID: 37478347, DOI: 10.1093/rheumatology/kead368.
• POS1258 RESULTS FROM A NOMINAL GROUP TECHNIQUE EXERCISE FOR THE CREATION OF A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: THE CRISTAL PROJECTLescoat A, Chen Y, Murphy S, Carroll L, Vann N, Didio P, Iya S, Phanhdone T, Farrington S, Allanore Y, Cella D, Chung L, Clements P, Del Galdo F, Denton C, Distler O, Hinchcliff M, Hughes M, Hummers L, Pauling J, Pope J, Steen V, Varga J, Buch M, Khanna D. POS1258 RESULTS FROM A NOMINAL GROUP TECHNIQUE EXERCISE FOR THE CREATION OF A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: THE CRISTAL PROJECT. 2023, 971.2-972. DOI: 10.1136/annrheumdis-2023-eular.4633.
• Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in SkinYang M, Goh V, Lee J, Espinoza M, Yuan Y, Carns M, Aren K, Chung L, Khanna D, McMahan ZH, Agrawal R, Nelson L, Shah SJ, Whitfield ML, Hinchcliff M. Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin. Arthritis Care & Research 2023, 75: 1469-1480. PMID: 35997480, PMCID: PMC9947190, DOI: 10.1002/acr.24998.
• Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosisFeher A, Miller E, Peters D, Mojibian H, Sinusas A, Hinchcliff M, Baldassarre L. Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis. Rheumatology International 2023, 43: 849-858. PMID: 36894756, DOI: 10.1007/s00296-023-05294-6.
• A Novel MIP-1-Expressing Macrophage Subtype in BAL Fluid from Healthy Volunteers.Reyfman PA, Malsin ES, Khuder B, Joshi N, Gadhvi G, Flozak AS, Carns MA, Aren K, Goldberg IA, Kim S, Alexander M, Sporn PHS, Misharin AV, Budinger GRS, Lam AP, Hinchcliff M, Gottardi CJ, Winter DR. A Novel MIP-1-Expressing Macrophage Subtype in BAL Fluid from Healthy Volunteers. American Journal Of Respiratory Cell And Molecular Biology 2023, 68: 176-185. PMID: 36174229, PMCID: PMC9986555, DOI: 10.1165/rcmb.2021-0123oc.
• Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma PatientsMakinde H, Dunn JLM, Gadhvi G, Carns M, Aren K, Chung AH, Muhammad LN, Song J, Cuda CM, Dominguez S, Pandolfino JE, D'Amico J, Budinger GS, Assassi S, Frech TM, Khanna D, Shaeffer A, Perlman H, Hinchcliff M, Winter DR. Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma Patients. Arthritis & Rheumatology 2023, 75: 595-608. PMID: 36281773, PMCID: PMC10165944, DOI: 10.1002/art.42380.
• Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenonTeaw S, Gupta A, Williams A, Wilson F, Sumpio B, Sumpio B, Hinchcliff M. Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon. Arthritis Research & Therapy 2023, 25: 10. PMID: 36670487, PMCID: PMC9854186, DOI: 10.1186/s13075-023-02990-3.
• Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung diseaseHiguero Sevilla J, Memon A, Hinchcliff M. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Arthritis Research & Therapy 2023, 25: 118. PMID: 37422652, PMCID: PMC10329300, DOI: 10.1186/s13075-023-03090-y.
• Correction: Learnings from clinical trials in patients with connective tissue disease‑associated interstitial lung diseaseHiguero Sevilla J, Memon A, Hinchcliff M. Correction: Learnings from clinical trials in patients with connective tissue disease‑associated interstitial lung disease. Arthritis Research & Therapy 2023, 25: 132. PMID: 37501068, PMCID: PMC10373245, DOI: 10.1186/s13075-023-03123-6.
• Epiregulin is a dendritic cell–derived EGFR ligand that maintains skin and lung fibrosisOdell I, Steach H, Gauld S, Reinke-Breen L, Karman J, Carr T, Wetter J, Phillips L, Hinchcliff M, Flavell R. Epiregulin is a dendritic cell–derived EGFR ligand that maintains skin and lung fibrosis. Science Immunology 2022, 7: eabq6691. PMID: 36490328, PMCID: PMC9840167, DOI: 10.1126/sciimmunol.abq6691.
• Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis–Associated Interstitial Lung DiseaseYang MM, Balmert LC, Marangoni RG, Carns M, Hinchcliff M, Korman BD, Varga J. Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis Care & Research 2022, 75: 152-157. PMID: 34251759, PMCID: PMC9233895, DOI: 10.1002/acr.24749.
• Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosisBhandari R, Yang H, Kosarek NN, Smith AE, Garlick JA, Hinchcliff M, Whitfield ML, Pioli PA. Human dermal fibroblast-derived exosomes induce macrophage activation in systemic sclerosis. Rheumatology 2022, 62: si114-si124. PMID: 35946522, PMCID: PMC9910573, DOI: 10.1093/rheumatology/keac453.
• Differences in symptom experience among patients with systemic sclerosis: a cluster analytic approach to identifying subgroupsMurphy SL, Chen YT, Lee YC, Carns M, Aren K, Korman B, Hinchcliff M, Varga J. Differences in symptom experience among patients with systemic sclerosis: a cluster analytic approach to identifying subgroups. Rheumatology 2022, 62: si64-si73. PMID: 35920770, PMCID: PMC9910572, DOI: 10.1093/rheumatology/keac444.
• 045 An EGFR ligand maintains scleroderma skin and lung fibrosisOdell I, Steach H, Gauld S, Carr T, Wetter J, Phillips L, Hinchcliff M, Flavell R. 045 An EGFR ligand maintains scleroderma skin and lung fibrosis. Journal Of Investigative Dermatology 2022, 142: s8. DOI: 10.1016/j.jid.2022.05.099.
• Clinical and Autoantibody Associations in Antinuclear Antibody–Positive Systemic Sclerosis Lacking Prototypic AutoantibodiesKruzer K, Marangoni R, Heckler I, Elhage A, Varga J, Hinchcliff M, Carns M, Aren K, Wielgosz A, Nuzzo M, Venkataraman I, Korman B. Clinical and Autoantibody Associations in Antinuclear Antibody–Positive Systemic Sclerosis Lacking Prototypic Autoantibodies. JCR Journal Of Clinical Rheumatology 2022, 29: 47-51. PMID: 35767831, PMCID: PMC10241190, DOI: 10.1097/rhu.0000000000001881.
• A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosisFranks JM, Toledo DM, Martyanov V, Wang Y, Huang S, Wood TA, Spino C, Chung L, Denton C, Derrett-Smith E, Gordon JK, Spiera R, Domsic R, Hinchcliff M, Khanna D, Whitfield ML. A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. Rheumatology 2022, 62: 19-28. PMID: 35751592, PMCID: PMC9788818, DOI: 10.1093/rheumatology/keac344.
• Lung Injury Induces Alveolar Type 2 Cell Hypertrophy and Polyploidy with Implications for Repair and Regeneration.Weng A, Maciel Herrerias M, Watanabe S, Welch LC, Flozak AS, Grant RA, Aillon RP, Dada LA, Han SH, Hinchcliff M, Misharin AV, Budinger GRS, Gottardi CJ. Lung Injury Induces Alveolar Type 2 Cell Hypertrophy and Polyploidy with Implications for Repair and Regeneration. American Journal Of Respiratory Cell And Molecular Biology 2022, 66: 564-576. PMID: 35202558, PMCID: PMC9116356, DOI: 10.1165/rcmb.2021-0356oc.
• High-throughput identification of autoantibodies that target the human exoproteomeWang EY, Dai Y, Rosen CE, Schmitt MM, Dong MX, Ferré EMN, Liu F, Yang Y, González-Hernández JA, Meffre E, Hinchcliff M, Koumpouras F, Lionakis MS, Ring AM. High-throughput identification of autoantibodies that target the human exoproteome. Cell Reports Methods 2022, 2: 100172. PMID: 35360706, PMCID: PMC8967185, DOI: 10.1016/j.crmeth.2022.100172.
• FDG PET vascular imaging in IgG4-RD: Potential and challengesPucar D, Hinchcliff M. FDG PET vascular imaging in IgG4-RD: Potential and challenges. Journal Of Nuclear Cardiology 2021, 29: 2934-2937. PMID: 34964084, DOI: 10.1007/s12350-021-02887-1.
• Cellular and Molecular Diversity in SclerodermaHinchcliff M, Garcia-Milian R, Di Donato S, Dill K, Bundschuh E, Galdo FD. Cellular and Molecular Diversity in Scleroderma. Seminars In Immunology 2021, 58: 101648. PMID: 35940960, DOI: 10.1016/j.smim.2022.101648.
• Heterogeneity of primary and secondary peristalsis in systemic sclerosis: A new model of “scleroderma esophagus”Carlson DA, Prescott JE, Germond E, Brenner D, Carns M, Correia CS, Tetreault M, McMahan ZH, Hinchcliff M, Kou W, Kahrilas PJ, Perlman HR, Pandolfino JE. Heterogeneity of primary and secondary peristalsis in systemic sclerosis: A new model of “scleroderma esophagus”. Neurogastroenterology & Motility 2021, 34: e14284. PMID: 34709690, PMCID: PMC9046463, DOI: 10.1111/nmo.14284.
• Association Between Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging and Adverse Events in Patients With Autoimmune Rheumatic DiseaseFeher A, Boutagy NE, Oikonomou EK, Liu YH, Miller EJ, Sinusas AJ, Hinchcliff M. Association Between Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging and Adverse Events in Patients With Autoimmune Rheumatic Disease. Circulation Cardiovascular Imaging 2021, 14: e012208. PMID: 34503339, PMCID: PMC8475774, DOI: 10.1161/circimaging.120.012208.
• Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic SclerosisShowalter K, Hoffmann A, Richardson C, Aaby D, Lee J, Dematte J, Agrawal R, Savas H, Wu X, Chang RW, Hinchcliff M. Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis. The Journal Of Rheumatology 2021, 48: 1830-1838. PMID: 34266985, PMCID: PMC8985598, DOI: 10.3899/jrheum.210533.
• Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis.Feher A, Boutagy NE, Oikonomou EK, Thorn S, Liu YH, Miller EJ, Sinusas AJ, Hinchcliff M. Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis. The Journal Of Rheumatology 2021, 48: 1574-1582. PMID: 34266986, PMCID: PMC10275580, DOI: 10.3899/jrheum.210040.
• Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohortJaafar S, Lescoat A, Huang S, Gordon J, Hinchcliff M, Shah AA, Assassi S, Domsic R, Bernstein EJ, Steen V, Elliott S, Hant F, Castelino FV, Shanmugam VK, Correia C, Varga J, Nagaraja V, Roofeh D, Frech T, Khanna D. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Research & Therapy 2021, 23: 170. PMID: 34127049, PMCID: PMC8201684, DOI: 10.1186/s13075-021-02548-1.
• Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung DiseaseAssassi S, Li N, Volkmann ER, Mayes MD, Rünger D, Ying J, Roth MD, Hinchcliff M, Khanna D, Frech T, Clements PJ, Furst DE, Goldin J, Bernstein EJ, Castelino FV, Domsic RT, Gordon JK, Hant FN, Shah AA, Shanmugam VK, Steen VD, Elashoff RM, Tashkin DP. Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease. Arthritis & Rheumatology 2021, 73: 1005-1013. PMID: 33350170, PMCID: PMC8169525, DOI: 10.1002/art.41627.
• A review and roadmap of the skin, lung and gut microbiota in systemic sclerosisTeaw S, Hinchcliff M, Cheng M. A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis. Rheumatology 2021, 60: 5498-5508. PMID: 33734316, PMCID: PMC8643452, DOI: 10.1093/rheumatology/keab262.
• Large‐Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung FibrosisBellocchi C, Ying J, Goldmuntz EA, Keyes‐Elstein L, Varga J, Hinchcliff ME, Lyons MA, McSweeney P, Furst DE, Nash R, Crofford LJ, Welch B, Goldin JG, Pinckney A, Mayes MD, Sullivan KM, Assassi S. Large‐Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis. Arthritis & Rheumatology 2021, 73: 660-670. PMID: 33131208, PMCID: PMC8005427, DOI: 10.1002/art.41570.
• Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic SclerosisCarnaru M, Hinchcliff M. Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis. Current Treatment Options In Rheumatology 2021, 7: 21-38. DOI: 10.1007/s40674-021-00171-4.
• Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trialWilson FP, Martin M, Yamamoto Y, Partridge C, Moreira E, Arora T, Biswas A, Feldman H, Garg AX, Greenberg JH, Hinchcliff M, Latham S, Li F, Lin H, Mansour SG, Moledina DG, Palevsky PM, Parikh CR, Simonov M, Testani J, Ugwuowo U. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial. The BMJ 2021, 372: m4786. PMID: 33461986, PMCID: PMC8034420, DOI: 10.1136/bmj.m4786.
• The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort StudyMoledina DG, Simonov M, Yamamoto Y, Alausa J, Arora T, Biswas A, Cantley LG, Ghazi L, Greenberg JH, Hinchcliff M, Huang C, Mansour SG, Martin M, Peixoto A, Schulz W, Subair L, Testani JM, Ugwuowo U, Young P, Wilson FP. The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study. American Journal Of Kidney Diseases 2021, 77: 490-499.e1. PMID: 33422598, PMCID: PMC7791318, DOI: 10.1053/j.ajkd.2020.12.007.
• Computer vision applied to dual-energy computed tomography images for precise calcinosis cutis quantification in patients with systemic sclerosisChandrasekaran AC, Fu Z, Kraniski R, Wilson FP, Teaw S, Cheng M, Wang A, Ren S, Omar IM, Hinchcliff ME. Computer vision applied to dual-energy computed tomography images for precise calcinosis cutis quantification in patients with systemic sclerosis. Arthritis Research & Therapy 2021, 23: 6. PMID: 33407814, PMCID: PMC7788847, DOI: 10.1186/s13075-020-02392-9.
• Gastroesophageal RefluxMasoud A, Hinchcliff M. Gastroesophageal Reflux. 2020, 179-191. DOI: 10.1007/978-3-030-53736-4_16.
• Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort studyWu Y, Kwakkenbos L, Henry R, Carrier M, Gagarine M, Harb S, Bourgeault A, Tao L, Carboni-Jiménez A, Negeri Z, Patten S, Bartlett S, Mouthon L, Varga J, Benedetti A, Thombs B, Advisors F, Fortuné C, Gietzen A, Guillot G, Lewis N, Richard M, Sauvé M, Welling J, Fligelstone K, Gottesman K, Leite C, Pérez E, Investigators S, Baron M, Malcarne V, Mayes M, Nielson W, Riggs R, Assassi S, Ells C, van den Ende C, Frech T, Harel D, Hinchcliff M, Hudson M, Johnson S, Larche M, Nguyen C, Pope J, Rannou F, Reyna T, Schouffoer A, Suarez-Almazor M, Agard C, Albert A, Bernstein E, Berthier S, Bissonnette L, Bruns A, Carreira P, Chaigne B, Chung L, Correia C, Denton C, Domsic R, Dunne J, Dunogue B, Farge-Bancel D, Fortin P, Gordon J, Granel-Rey B, Hatron P, Herrick A, Hoa S, Jones N, de B. Fernandes A, Kafaja S, Khalidi N, Launay D, Manning J, Marie I, Martin M, Mekinian A, Melchor S, Nikpour M, Olagne L, Proudman S, Régent A, Rivière S, Robinson D, Rodriguez E, Roux S, Sobanski V, Steen V, Sutton E, Thorne C, Wilcox P, Ayala M, Carboni-Jiménez A, Gagarine M, Nordlund J, Østbø N, Rice D, Turner K, Culos-Reed N, Dyas L, El-Baalbaki G, Hebblethwaite S, Bustamante L, Duchek D, Ellis K. Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. Journal Of Psychosomatic Research 2020, 140: 110314. PMID: 33271402, PMCID: PMC7685938, DOI: 10.1016/j.jpsychores.2020.110314.
• Molecular “omic” signatures in systemic sclerosisMehta BK, Department of Molecular and Systems Biology G, Espinoza M, Hinchcliff M, Whitfield M, Department of Rheumatology A, Department of Biomedical Data Science D. Molecular “omic” signatures in systemic sclerosis. European Journal Of Rheumatology 2020, 7: 173-180. PMID: 33164732, PMCID: PMC7647683, DOI: 10.5152/eurjrheum.2020.19192.
• Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyThombs B, Kwakkenbos L, Henry R, Carrier M, Patten S, Harb S, Bourgeault A, Tao L, Bartlett S, Mouthon L, Varga J, Benedetti A, Advisors F, Fortuné C, Gietzen A, Guillot G, Lewis N, Richard M, Sauvé M, Welling J, Fligelstone K, Gottesman K, Leite C, Pérez E, Investigators S, Baron M, Malcarne V, Mayes M, Nielson W, Riggs R, Assassi S, Ells C, van den Ende C, Frech T, Harel D, Hinchcliff M, Hudson M, Johnson S, Larche M, Nguyen C, Pope J, Rannou F, Reyna T, Schouffoer A, Suarez-Almazor M, Agard C, Albert A, Bernstein E, Berthier S, Bissonnette L, Bruns A, Carreira P, Chaigne B, Chung L, Correia C, Denton C, Domsic R, Dunne J, Dunogue B, Farge-Bancel D, Fortin P, Gordon J, Granel-Rey B, Hatron P, Herrick A, Hoa S, Jones N, de B. Fernandes A, Kafaja S, Khalidi N, Launay D, Manning J, Marie I, Martin M, Mekinian A, Melchor S, Nikpour M, Olagne L, Proudman S, Régent A, Rivière S, Robinson D, Rodriguez E, Roux S, Sobanski V, Steen V, Sutton E, Thorne C, Wilcox P, Ayala M, Carboni-Jiménez A, Gagarine M, Nordlund J, Østbø N, Rice D, Turner K, Culos-Reed N, Dyas L, El-Baalbaki G, Hebblethwaite S, Bustamante L, Duchek D, Ellis K. Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Journal Of Psychosomatic Research 2020, 139: 110262. PMID: 33070043, PMCID: PMC7532799, DOI: 10.1016/j.jpsychores.2020.110262.
• Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic SclerosisBernstein EJ, Jaafar S, Assassi S, Domsic RT, Frech TM, Gordon JK, Broderick RJ, Hant FN, Hinchcliff ME, Shah AA, Shanmugam VK, Steen VD, Khanna D. Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology 2020, 72: 1892-1896. PMID: 32583956, PMCID: PMC7722107, DOI: 10.1002/art.41415.
• Regulator combinations identify systemic sclerosis patients with more severe diseaseWang Y, Franks JM, Yang M, Toledo DM, Wood TA, Hinchcliff M, Whitfield ML. Regulator combinations identify systemic sclerosis patients with more severe disease. JCI Insight 2020, 5: e137567. PMID: 32721949, PMCID: PMC7526449, DOI: 10.1172/jci.insight.137567.
• Mast cell activation in the systemic sclerosis esophagusTom K, Mehta BK, Hoffmann A, Aren K, Carns M, Lee J, Martyanov V, Popovich D, Kosarek N, Wood T, Brenner D, Carlson DA, Ostilla L, Willcocks E, Bryce P, Wechsler JB, Whitfield ML, Hinchcliff M. Mast cell activation in the systemic sclerosis esophagus. Journal Of Scleroderma And Related Disorders 2020, 6: 77-86. PMID: 34179507, PMCID: PMC8225255, DOI: 10.1177/2397198320941322.
• Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic SclerosisHinchcliff M. Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology 2020, 72: 1237-1240. PMID: 32368869, PMCID: PMC7641910, DOI: 10.1002/art.41302.
• Current and Potential New Targets in Systemic Sclerosis Therapy: a New HopeHinchcliff M, O’Reilly S. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Current Rheumatology Reports 2020, 22: 42. PMID: 32562016, PMCID: PMC7305248, DOI: 10.1007/s11926-020-00918-3.
• Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosisValenzuela A, Baron M, Rodriguez-Reyna TS, Proudman S, Khanna D, Young A, Hinchcliff M, Steen V, Gordon J, Hsu V, Castelino FV, Schoenfeld S, Li S, Wu JY, Fiorentino D, Chung L. Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Seminars In Arthritis And Rheumatism 2020, 50: 891-896. PMID: 32898758, PMCID: PMC8205269, DOI: 10.1016/j.semarthrit.2020.06.007.
• Profibrotic Activation of Human Macrophages in Systemic SclerosisBhandari R, Ball MS, Martyanov V, Popovich D, Schaafsma E, Han S, ElTanbouly M, Orzechowski NM, Carns M, Arroyo E, Aren K, Hinchcliff M, Whitfield ML, Pioli PA. Profibrotic Activation of Human Macrophages in Systemic Sclerosis. Arthritis & Rheumatology 2020, 72: 1160-1169. PMID: 32134204, PMCID: PMC7329566, DOI: 10.1002/art.41243.
• Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patientsThombs B, Kwakkenbos L, Carrier M, Bourgeault A, Tao L, Harb S, Gagarine M, Rice D, Bustamante L, Ellis K, Duchek D, Wu Y, Bhandari P, Neupane D, Carboni-Jiménez A, Henry R, Krishnan A, Sun Y, Levis B, He C, Turner K, Benedetti A, Culos-Reed N, El-Baalbaki G, Hebblethwaite S, Bartlett S, Dyas L, Patten S, Varga J, Team S, Fortuné C, Gietzen A, Guillot G, Lewis N, Nielsen K, Richard M, Sauvé M, Welling J, Investigators S, Baron M, Furst D, Gottesman K, Malcarne V, Mayes M, Mouthon L, Nielson W, Riggs R, Wigley F, Assassi S, Boutron I, Ells C, van den Ende C, Fligelstone K, Frech T, Godard D, Harel D, Hinchcliff M, Hudson M, Johnson S, Larche M, Leite C, Nguyen C, Pope J, Portales A, Rannou F, Reyna T, Schouffoer A, Suarez-Almazor M, Agard C, Albert A, André M, Arsenault G, Benzidia I, Bernstein E, Berthier S, Bissonnette L, Boire G, Bruns A, Carreira P, Casadevall M, Chaigne B, Chung L, Cohen P, Correia C, Dagenais P, Denton C, Domsic R, Dubois S, Dunne J, Dunogue B, Fare R, Farge-Bancel D, Fortin P, Gill A, Gordon J, Granel-Rey B, Gyger G, Hachulla E, Hatron P, Herrick A, Hij A, Hoa S, Ikic A, Jones N, de B. Fernandes A, Kafaja S, Khalidi N, Lambert M, Launay D, Liang P, Maillard H, Maltez N, Manning J, Marie I, Martin M, Martin T, Masetto A, Maurier F, Mekinian A, Melchor S, Nikpour M, Olagne L, Poindron V, Proudman S, Régent A, Rivière S, Robinson D, Rodriguez E, Roux S, Smets P, Smith D, Sobanski V, Spiera R, Steen V, Stevens W, Sutton E, Terrier B, Thorne C, Varga J, Wilcox P, Ayala M, Ostbo N. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal Of Psychosomatic Research 2020, 135: 110132. PMID: 32521358, PMCID: PMC7224675, DOI: 10.1016/j.jpsychores.2020.110132.
• Single-Cell Transcriptomic Profiling of Bronchoalveolar Lavage Fluid from Healthy Volunteers Identifies a Subpopulation of Alveolar Macrophages Enriched for Inflammatory PathwaysReyfman P, Malsin E, Alexander M, Flozak A, Kim S, Misharin A, Sporn P, Lam A, Hinchcliff M, Budinger G, Gottardi C, Winter D. Single-Cell Transcriptomic Profiling of Bronchoalveolar Lavage Fluid from Healthy Volunteers Identifies a Subpopulation of Alveolar Macrophages Enriched for Inflammatory Pathways. 2020, a2975-a2975. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2975.
• Pro-fibrotic Activation of Human Macrophages in Systemic SclerosisBhandari R, Ball M, Martyanov V, Popovich D, Schaafsma E, Han S, Eltanbouly M, Carns M, Arroyo E, Aren K, Hinchcliff M, Whitfield M, Pioli P. Pro-fibrotic Activation of Human Macrophages in Systemic Sclerosis. The Journal Of Immunology 2020, 204: 224.33-224.33. DOI: 10.4049/jimmunol.204.supp.224.33.
• Circulating classical monocytes share a common transcriptional signature with skin macrophages in Systemic SclerosisMakinde H, Dominguez S, Cuda C, Gadhvi G, Aren K, Zeng C, Eickelberg G, Khanna D, Assassi S, Frech T, Winter D, Perlman H, Hinchcliff M. Circulating classical monocytes share a common transcriptional signature with skin macrophages in Systemic Sclerosis. The Journal Of Immunology 2020, 204: 152.12-152.12. DOI: 10.4049/jimmunol.204.supp.152.12.
• High-throughput quantitative histology in systemic sclerosis skin disease using computer visionCorreia C, Mawe S, Lofgren S, Marangoni RG, Lee J, Saber R, Aren K, Cheng M, Teaw S, Hoffmann A, Goldberg I, Cowper SE, Khatri P, Hinchcliff M, Mahoney JM. High-throughput quantitative histology in systemic sclerosis skin disease using computer vision. Arthritis Research & Therapy 2020, 22: 48. PMID: 32171325, PMCID: PMC7071594, DOI: 10.1186/s13075-020-2127-0.
• IMPAIRED CORONARY FLOW RESERVE ON 82RUBIDIUM POSITRON EMISSION TOMOGRAPHY IMAGING PREDICTS ADVERSE EVENTS IN PATIENTS WITH AUTOIMMUNE DISEASEFeher A, Boutagy N, Oikonomou E, Miller E, Sinusas A, Hinchcliff M. IMPAIRED CORONARY FLOW RESERVE ON 82RUBIDIUM POSITRON EMISSION TOMOGRAPHY IMAGING PREDICTS ADVERSE EVENTS IN PATIENTS WITH AUTOIMMUNE DISEASE. Journal Of The American College Of Cardiology 2020, 75: 1726. DOI: 10.1016/s0735-1097(20)32353-6.
• Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profileSkaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, Hant FN, Gordon JK, Shah AA, Zhu L, Zheng WJ, Browning JL, Barron AMS, Wu M, Visvanathan S, Baum P, Franks JM, Whitfield ML, Shanmugam VK, Domsic RT, Castelino FV, Bernstein EJ, Wareing N, Lyons MA, Ying J, Charles J, Mayes MD, Assassi S. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Annals Of The Rheumatic Diseases 2019, 79: annrheumdis-2019-215894. PMID: 31767698, PMCID: PMC7386329, DOI: 10.1136/annrheumdis-2019-215894.
• Connective Tissue Disease–Associated Interstitial Lung Disease Evaluation and ManagementAntin-Ozerkis D, Hinchcliff M. Connective Tissue Disease–Associated Interstitial Lung Disease Evaluation and Management. Clinics In Chest Medicine 2019, 40: 617-636. PMID: 31376896, DOI: 10.1016/j.ccm.2019.05.008.
• Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesAssassi S, Wang X, Chen G, Goldmuntz E, Keyes-Elstein L, Ying J, Wallace PK, Turner J, Zheng WJ, Pascual V, Varga J, Hinchcliff ME, Bellocchi C, McSweeney P, Furst DE, Nash RA, Crofford LJ, Welch B, Pinckney A, Mayes MD, Sullivan KM. Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Annals Of The Rheumatic Diseases 2019, 78: 1371. PMID: 31391177, PMCID: PMC7167108, DOI: 10.1136/annrheumdis-2019-215770.
• Towards a new classification of systemic sclerosisHinchcliff M, Mahoney JM. Towards a new classification of systemic sclerosis. Nature Reviews Rheumatology 2019, 15: 456-457. PMID: 31217541, DOI: 10.1038/s41584-019-0257-z.
• Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary FibrosisReyfman PA, Walter JM, Joshi N, Anekalla KR, McQuattie-Pimentel AC, Chiu S, Fernandez R, Akbarpour M, Chen CI, Ren Z, Verma R, Abdala-Valencia H, Nam K, Chi M, Han S, Gonzalez-Gonzalez FJ, Soberanes S, Watanabe S, Williams KJN, Flozak AS, Nicholson TT, Morgan VK, Winter DR, Hinchcliff M, Hrusch CL, Guzy RD, Bonham CA, Sperling AI, Bag R, Hamanaka RB, Mutlu GM, Yeldandi AV, Marshall SA, Shilatifard A, Amaral LAN, Perlman H, Sznajder JI, Argento AC, Gillespie CT, Dematte J, Jain M, Singer BD, Ridge KM, Lam AP, Bharat A, Bhorade SM, Gottardi CJ, Budinger GRS, Misharin AV. Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2019, 199: 1517-1536. PMID: 30554520, PMCID: PMC6580683, DOI: 10.1164/rccm.201712-2410oc.
• The Prognostic Value of Monocyte Count in Idiopathic Pulmonary Fibrosis: A Multi-Omic Cohort StudyScott M, Quinn K, Li Q, Carroll R, Chen S, Carns M, Aren K, Sun J, Koloms K, Lee J, Kropski J, Zhao H, Herzog E, Martinez F, Moore B, Hinchcliff M, Denny J, Kaminski N, Herazo-Maya J, Shah N, Khatri P. The Prognostic Value of Monocyte Count in Idiopathic Pulmonary Fibrosis: A Multi-Omic Cohort Study. 2019, a7342-a7342. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7342.
• Complementary therapies for patients with systemic sclerosisShowalter K, Hoffmann A, DeCredico N, Thakrar A, Arroyo E, Goldberg I, Hinchcliff M. Complementary therapies for patients with systemic sclerosis. Journal Of Scleroderma And Related Disorders 2019, 4: 187-199. PMID: 35382503, PMCID: PMC8922560, DOI: 10.1177/2397198319833503.
• Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort studyScott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, Chen S, Carns MA, Aren K, Sun J, Koloms K, Lee J, Baral J, Kropski J, Zhao H, Herzog E, Martinez FJ, Moore BB, Hinchcliff M, Denny J, Kaminski N, Herazo-Maya JD, Shah NH, Khatri P. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. The Lancet Respiratory Medicine 2019, 7: 497-508. PMID: 30935881, PMCID: PMC6529612, DOI: 10.1016/s2213-2600(18)30508-3.
• Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study.Fox RS, Kwakkenbos L, Carrier ME, Mills SD, Gholizadeh S, Jewett LR, Roesch SC, Merz EL, Assassi S, Furst DE, Gottesman K, Mayes MD, Thombs BD, Malcarne VL, and the SPIN Investigators.. Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care Res (Hoboken) 2018, 70:1646-1652.
• Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS RegistryHsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. The Journal Of Rheumatology 2018, 46: 176-183. PMID: 30275260, DOI: 10.3899/jrheum.180018.
• Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic SclerosisShowalter K, Hoffmann A, Rouleau G, Aaby D, Lee J, Richardson C, Dematte J, Agrawal R, Chang RW, Hinchcliff M. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis. The Journal Of Rheumatology 2018, 45: 1572-1576. PMID: 30275265, PMCID: PMC6214765, DOI: 10.3899/jrheum.171362.
• The novel adipokine C1q-TNF related protein 9 (CTRP9) is elevated in systemic sclerosis-associated interstitial lung disease.Korman B, Alejo R, Sudhakar D, Hinchcliff M, Agrawal R, Varga J, Marangoni RG. The novel adipokine C1q-TNF related protein 9 (CTRP9) is elevated in systemic sclerosis-associated interstitial lung disease. Clinical And Experimental Rheumatology 2018, 36 Suppl 113: 184-185. PMID: 30183591, PMCID: PMC7389309.
• Normal Values of Esophageal Distensibility and Distension-Induced Contractility Measured by Functional Luminal Imaging Probe PanometryCarlson DA, Kou W, Lin Z, Hinchcliff M, Thakrar A, Falmagne S, Prescott J, Dorian E, Kahrilas PJ, Pandolfino JE. Normal Values of Esophageal Distensibility and Distension-Induced Contractility Measured by Functional Luminal Imaging Probe Panometry. Clinical Gastroenterology And Hepatology 2018, 17: 674-681.e1. PMID: 30081222, PMCID: PMC6360138, DOI: 10.1016/j.cgh.2018.07.042.
• SAT0486 Myeloablation followed by autologous stem cell rescue leads to normalisation of serum il-6 levels in patients with systemic sclerosisBellocchi C, Sullivan K, Goldmuntz E, Ying J, Keyes-Elstein L, Varga J, Hinchcliff M, McSweeney P, Furst D, Nash R, Crofford L, Welch B, Pinckney A, Mayes M, Assassi S. SAT0486 Myeloablation followed by autologous stem cell rescue leads to normalisation of serum il-6 levels in patients with systemic sclerosis. Annals Of The Rheumatic Diseases 2018, 77: 1100. DOI: 10.1136/annrheumdis-2018-eular.3731.
• THU0387 High-throughput quantitative histology in systemic sclerosis skin disease using computer visionCorreia C, Hinchcliff M, Mahoney M. THU0387 High-throughput quantitative histology in systemic sclerosis skin disease using computer vision. Annals Of The Rheumatic Diseases 2018, 77: 408. DOI: 10.1136/annrheumdis-2018-eular.7587.
• The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohortsDougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Sauvé M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larché M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD, Albert A, Arsenault G, Bissonette L, Boutron I, Carreira P, Maia A, Dagenais P, Domsic R, El-Baalbaki G, Ells C, van den Ende C, Fligelstone K, Fortune C, Godard D, Gyger G, Harel D, Ikic A, Impens A, Jang Y, Artur Jose de B, Kennedy A, Khalidi N, Korman B, Leite C, Liang P, Marra C, Masetto A, Nielsen K, Portales A, Riggs R, Reyna T, Roux S, Schouffoer A, Steele R, Suarez-Almazor M, Varga J, Welling J, Wigley F, Wong-Rieger D, Cumin J, Delisle V, Fedoruk C, Fox R, Gholizadeh S, Jewett L, Levis B, Mills S, Pepin M, Persmann J, Turner K. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology 2018, 57: 1623-1631. PMID: 29868924, DOI: 10.1093/rheumatology/key139.
• Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound‐Guided Synovial Biopsies in Rheumatoid ArthritisMandelin AM, Homan PJ, Shaffer AM, Cuda CM, Dominguez ST, Bacalao E, Carns M, Hinchcliff M, Lee J, Aren K, Thakrar A, Montgomery AB, Bridges SL, Bathon JM, Atkinson JP, Fox DA, Matteson EL, Buckley CD, Pitzalis C, Parks D, Hughes LB, Geraldino‐Pardilla L, Ike R, Phillips K, Wright K, Filer A, Kelly S, Ruderman EM, Morgan V, Abdala‐Valencia H, Misharin AV, Budinger GS, Bartom ET, Pope RM, Perlman H, Winter DR. Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound‐Guided Synovial Biopsies in Rheumatoid Arthritis. Arthritis & Rheumatology 2018, 70: 841-854. PMID: 29439295, PMCID: PMC5984677, DOI: 10.1002/art.40453.
• Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosisLee DC, Hinchcliff ME, Sarnari R, Stark MM, Lee J, Koloms K, Hoffmann A, Carns M, Thakrar A, Aren K, Varga J, Aquino A, Carr JC, Benefield BC, Shah SJ. Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis. Journal Of Scleroderma And Related Disorders 2018, 3: 159-169. PMID: 29808171, PMCID: PMC5969530, DOI: 10.1177/2397198318762888.
• Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in SkinHinchcliff M, Toledo DM, Taroni JN, Wood TA, Franks JM, Ball MS, Hoffmann A, Amin SM, Tan AU, Tom K, Nesbeth Y, Lee J, Ma M, Aren K, Carns MA, Pioli PA, Whitfield ML. Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. Journal Of Investigative Dermatology 2018, 138: 1301-1310. PMID: 29391252, PMCID: PMC6590516, DOI: 10.1016/j.jid.2018.01.006.
• Abnormal esophageal acid exposure on high‐dose proton pump inhibitor therapy is common in systemic sclerosis patientsStern EK, Carlson DA, Falmagne S, Hoffmann AD, Carns M, Pandolfino JE, Hinchcliff M, Brenner DM. Abnormal esophageal acid exposure on high‐dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterology & Motility 2017, 30 PMID: 29110377, PMCID: PMC5771836, DOI: 10.1111/nmo.13247.
• Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic SclerosisKorman BD, Marangoni RG, Hinchcliff M, Shah SJ, Carns M, Hoffmann A, Ramsey‐Goldman R, Varga J. Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis & Rheumatology 2017, 69: 2062-2068. PMID: 28651038, PMCID: PMC5748338, DOI: 10.1002/art.40193.
• Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life spanMisharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie-Pimentel AC, Chen CI, Anekalla KR, Joshi N, Williams KJN, Abdala-Valencia H, Yacoub TJ, Chi M, Chiu S, Gonzalez-Gonzalez FJ, Gates K, Lam AP, Nicholson TT, Homan PJ, Soberanes S, Dominguez S, Morgan VK, Saber R, Shaffer A, Hinchcliff M, Marshall SA, Bharat A, Berdnikovs S, Bhorade SM, Bartom ET, Morimoto RI, Balch WE, Sznajder JI, Chandel NS, Mutlu GM, Jain M, Gottardi CJ, Singer BD, Ridge KM, Bagheri N, Shilatifard A, Budinger GRS, Perlman H. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. Journal Of Experimental Medicine 2017, 214: 2387-2404. PMID: 28694385, PMCID: PMC5551573, DOI: 10.1084/jem.20162152.
• A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosisTaroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Medicine 2017, 9: 27. PMID: 28330499, PMCID: PMC5363043, DOI: 10.1186/s13073-017-0417-1.
• Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort.Gordon JK, Girish G, Berrocal VJ, Zhang M, Hatzis C, Assassi S, Bernstein EJ, Domsic RT, Hant FN, Hinchcliff M, Schiopu E, Steen VD, Frech TM, Khanna D. Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. The Journal Of Rheumatology 2017, 44: 791-794. PMID: 28298560, PMCID: PMC5457319, DOI: 10.3899/jrheum.160654.
• Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort.Jewett LR, Kwakkenbos L, Carrier ME, Malcarne VL, Harcourt D, Rumsey N, Mayes MD, Assassi S, Körner A, Fox RS, Gholizadeh S, Mills SD, Fortune C, Thombs BD, Baron M, Bartlett SJ, Furst D, Gottesman K, van den Hoogen F, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauve M, Wigley F, Boutron I, Costa Maia A, El-Baalbaki G, Ells C, van den Ende C, Fligelstone K, Fortune C, Frech T, Godard D, Harel D, Hudson M, Impens A, Jang Y, Johnson SR, Kennedy AT, Khanna D, Larche M, Leite C, Marra C, Nielsen K, Poole JL, Pope J, Rodriguez Reyna TS, Schouffoer AA, Steele RJ, Suarez-Almazor ME, Welling J, Wong-Rieger D, Albert A, Arsenault G, Bissonnette L, Boire G, Bruns A, Carreira P, Chung L, Dagenais P, Denton C, Domsic R, Dunne JV, Fortin P, Gill A, Gordon J, Gyger G, Herrick AL, Hinchcliff M, Ikic A, Jones N, de B Fernandes AJ, Kafaja S, Khalidi N, Korman B, Liang P, Manning J, Masetto A, Portales A, Robinson D, Roux S, Schiopu E, Smith D, Spiera R, Steen V, Sutton E, Thorne C, Varga J, Wilcox P, Delisle VC, Fedoruk C, Levis B, Pepin MR, Persmann J. Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image 2017, 20: 99-106. PMID: 28068643, DOI: 10.1016/j.bodyim.2016.11.007.
• Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severityLofgren S, Hinchcliff M, Carns M, Wood T, Aren K, Arroyo E, Cheung P, Kuo A, Valenzuela A, Haemel A, Wolters PJ, Gordon J, Spiera R, Assassi S, Boin F, Chung L, Fiorentino D, Utz PJ, Whitfield ML, Khatri P. Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. JCI Insight 2016, 1: e89073. PMID: 28018971, PMCID: PMC5161207, DOI: 10.1172/jci.insight.89073.
• Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical And Experimental Rheumatology 2016, 35 Suppl 106: 106-113. PMID: 27908301.
• Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic SclerosisHinchcliff M, Whitfield M. Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis. 2016, 657-670. DOI: 10.1007/978-3-319-31407-5_49.
• Controversies: molecular vs. clinical systemic sclerosis classificationJohnson S, Hinchcliff M, Asano Y. Controversies: molecular vs. clinical systemic sclerosis classification. Journal Of Scleroderma And Related Disorders 2016, 1: 277-285. DOI: 10.5301/jsrd.5000213.
• Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Investigators S. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. The Lancet Respiratory Medicine 2016, 4: 708-719. PMID: 27469583, PMCID: PMC5014629, DOI: 10.1016/s2213-2600(16)30152-7.
• Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylateHinchcliff ME, Lomasney J, Johnson JA, Varga J. Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylate. Rheumatology 2016, 55: 1916-1918. PMID: 27338086, PMCID: PMC5854093, DOI: 10.1093/rheumatology/kew245.
• Tenascin-C drives persistence of organ fibrosisBhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, Lafyatis R, Lee J, Hinchcliff M, Feghali-Bostwick C, Lakota K, Budinger GR, Raparia K, Tamaki Z, Varga J. Tenascin-C drives persistence of organ fibrosis. Nature Communications 2016, 7: 11703. PMID: 27256716, PMCID: PMC4895803, DOI: 10.1038/ncomms11703.
• Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium studyValenzuela A, Baron M, Group C, Herrick AL, Proudman S, Stevens W, Group A, Rodriguez-Reyna TS, Vacca A, Medsger TA, Hinchcliff M, Hsu V, Wu JY, Fiorentino D, Chung L. Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. Seminars In Arthritis And Rheumatism 2016, 46: 344-349. PMID: 27371996, PMCID: PMC5500288, DOI: 10.1016/j.semarthrit.2016.05.008.
• Comment on “Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study”Hoffmann A, Lee J, Ma M, Agrawal R, Chang RW, Richardson C, Hinchcliff M, Showalter K. Comment on “Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study”. Seminars In Arthritis And Rheumatism 2016, 46: e11-e12. PMID: 27312382, PMCID: PMC6701947, DOI: 10.1016/j.semarthrit.2016.04.006.
• Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic SclerosisCarlson DA, Crowell MD, Kimmel JN, Patel A, Gyawali CP, Hinchcliff M, Griffing WL, Pandolfino JE, Vela MF. Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic Sclerosis. Clinical Gastroenterology And Hepatology 2016, 14: 1502-1506. PMID: 27062902, PMCID: PMC5028229, DOI: 10.1016/j.cgh.2016.03.039.
• Su1026 Esophageal Dilation and Health-Related Quality of Life in Systemic SclerosisBlanco M, Ma M, Lee J, Agrawal R, Chang R, Hinchcliff M. Su1026 Esophageal Dilation and Health-Related Quality of Life in Systemic Sclerosis. Gastroenterology 2016, 150: s447. DOI: 10.1016/s0016-5085(16)31554-2.
• The association between systemic sclerosis disease manifestations and esophageal high‐resolution manometry parametersKimmel JN, Carlson DA, Hinchcliff M, Carns MA, Aren KA, Lee J, Pandolfino JE. The association between systemic sclerosis disease manifestations and esophageal high‐resolution manometry parameters. Neurogastroenterology & Motility 2016, 28: 1157-1165. PMID: 26921101, PMCID: PMC4956560, DOI: 10.1111/nmo.12813.
• Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional studyRichardson C, Agrawal R, Lee J, Almagor O, Nelson R, Varga J, Cuttica MJ, Dematte J, Chang RW, Hinchcliff ME. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. Seminars In Arthritis And Rheumatism 2016, 46: 109-114. PMID: 27033049, PMCID: PMC5500283, DOI: 10.1016/j.semarthrit.2016.02.004.
• The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosisZiemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology 2016, 55: 911-917. PMID: 26880832, PMCID: PMC5854039, DOI: 10.1093/rheumatology/kew003.
• Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patientsWu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martín J, Varga J, Mayes MD. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Research & Therapy 2016, 18: 20. PMID: 26792595, PMCID: PMC4719560, DOI: 10.1186/s13075-016-0923-3.
• Scleroderma: From Pathogenesis to Comprehensive Management, 2e.Hinchcliff M, Whitfield M. Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis. 2016. Invited book chapter.
• Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signaturesTaroni JN, Martyanov V, Huang CC, Mahoney JM, Hirano I, Shetuni B, Yang GY, Brenner D, Jung B, Wood TA, Bhattacharyya S, Almagor O, Lee J, Sirajuddin A, Varga J, Chang RW, Whitfield ML, Hinchcliff M. Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. Arthritis Research & Therapy 2015, 17: 194. PMID: 26220546, PMCID: PMC4518531, DOI: 10.1186/s13075-015-0695-1.
• Survival in systemic sclerosis–pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) RegistryHinchcliff M, Khanna S, Hsu VM, Lee J, Almagor O, Chang RW, Steen V, Chung L, Investigators T. Survival in systemic sclerosis–pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Seminars In Arthritis And Rheumatism 2015, 45: 309-314. PMID: 26210782, PMCID: PMC4656087, DOI: 10.1016/j.semarthrit.2015.06.011.
• Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case reportFrech TM, Revelo MP, Ryan JJ, Shah AA, Gordon J, Domsic R, Hant F, Assassi S, Shanmugam VK, Hinchcliff M, Steen V, Khanna D, Bernstein EJ, Cox J, Luem N, Drakos S. Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. Journal Of Medical Case Reports 2015, 9: 136. PMID: 26055398, PMCID: PMC4469401, DOI: 10.1186/s13256-015-0587-7.
• A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosisMarangoni RG, Korman BD, Allanore Y, Dieude P, Armstrong LL, Rzhetskaya M, Hinchcliff M, Carns M, Podlusky S, Shah SJ, Ruiz B, Hachulla E, Tiev K, Cracowski JL, Varga J, Hayes MG. A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis. Arthritis Research & Therapy 2015, 17: 128. PMID: 25986483, PMCID: PMC4437446, DOI: 10.1186/s13075-015-0641-2.
• The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β SignalingWei J, Ghosh AK, Chu H, Fang F, Hinchcliff ME, Wang J, Marangoni RG, Varga J. The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling. Arthritis & Rheumatology 2015, 67: 1323-1334. PMID: 25707573, PMCID: PMC4518870, DOI: 10.1002/art.39061.
• Tu1412 Esophageal Motility of Patients With Systemic Sclerosis Evaluated Using High-Resolution ManometryKimmel J, Carlson D, Hinchcliff M, Carns M, Aren K, Pandolfino J. Tu1412 Esophageal Motility of Patients With Systemic Sclerosis Evaluated Using High-Resolution Manometry. Gastroenterology 2015, 148: s-882-s-883. DOI: 10.1016/s0016-5085(15)32999-1.
• Tu1157 Esophageal Peristaltic Reserve in Patients With Systemic Sclerosis: A Study Assessing Multiple Rapid Swallow Response Utilizing High-Resolution ManometryKimmel J, Carlson D, Hinchcliff M, Carns M, Aren K, Pandolfino J. Tu1157 Esophageal Peristaltic Reserve in Patients With Systemic Sclerosis: A Study Assessing Multiple Rapid Swallow Response Utilizing High-Resolution Manometry. Gastroenterology 2015, 148: s-806. DOI: 10.1016/s0016-5085(15)32745-1.
• Serum Amyloid A Is a Marker for Pulmonary Involvement in Systemic SclerosisLakota K, Carns M, Podlusky S, Mrak-Poljsak K, Hinchcliff M, Lee J, Tomsic M, Sodin-Semrl S, Varga J. Serum Amyloid A Is a Marker for Pulmonary Involvement in Systemic Sclerosis. PLOS ONE 2015, 10: e0110820. PMID: 25629975, PMCID: PMC4321755, DOI: 10.1371/journal.pone.0110820.
• Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent CohortsJohnson ME, Mahoney JM, Taroni J, Sargent JL, Marmarelis E, Wu MR, Varga J, Hinchcliff ME, Whitfield ML. Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent Cohorts. PLOS ONE 2015, 10: e0114017. PMID: 25607805, PMCID: PMC4301872, DOI: 10.1371/journal.pone.0114017.
• Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic PolymorphismsMahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, Hinchcliff ME, Whitfield ML. Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms. PLOS Computational Biology 2015, 11: e1004005. PMID: 25569146, PMCID: PMC4288710, DOI: 10.1371/journal.pcbi.1004005.
• Advances in the Evaluation and Management of Esophageal Disease of Systemic SclerosisCarlson DA, Hinchcliff M, Pandolfino JE. Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis. Current Rheumatology Reports 2014, 17: 475. PMID: 25475597, PMCID: PMC4343525, DOI: 10.1007/s11926-014-0475-y.
• Antinuclear antibody-negative systemic sclerosisSalazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. Seminars In Arthritis And Rheumatism 2014, 44: 680-686. PMID: 25578738, PMCID: PMC4447614, DOI: 10.1016/j.semarthrit.2014.11.006.
• Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.Fischer A, Swigris J, Bolster M, Chung L, Csuka M, Domsic R, Frech T, Hinchcliff M, Hsu V, Hummers L, Gomberg-Maitland M, Mathai S, Simms R, Steen V. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clinical And Experimental Rheumatology 2014, 32: s-109-14. PMID: 25372796.
• Longitudinal Evaluation of PROMIS-29 and FACIT-Dyspnea Short Forms in Systemic SclerosisHinchcliff ME, Beaumont JL, Carns MA, Podlusky S, Thavarajah K, Varga J, Cella D, Chang RW. Longitudinal Evaluation of PROMIS-29 and FACIT-Dyspnea Short Forms in Systemic Sclerosis. The Journal Of Rheumatology 2014, 42: 64-72. PMID: 25362656, PMCID: PMC4480645, DOI: 10.3899/jrheum.140143.
• FibronectinEDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor SignalingBhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getsios S, White ES, Varga J. FibronectinEDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling. Science Translational Medicine 2014, 6: 232ra50. PMID: 24739758, PMCID: PMC4414050, DOI: 10.1126/scitranslmed.3008264.
• Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort studyHsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars In Arthritis And Rheumatism 2014, 44: 55-62. PMID: 24709277, DOI: 10.1016/j.semarthrit.2014.03.002.
• Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma RegistryChung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg‐Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD. Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Arthritis Care & Research 2014, 66: 489-495. PMID: 23983198, DOI: 10.1002/acr.22121.
• Systemic sclerosis: beyond limited and diffuse subsets?Varga J, Hinchcliff M. Systemic sclerosis: beyond limited and diffuse subsets? Nature Reviews Rheumatology 2014, 10: 200-202. PMID: 24535544, PMCID: PMC5438483, DOI: 10.1038/nrrheum.2014.22.
• Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic SclerosisMayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, Assassi S, Ying J, Tan FK, Arnett FC, Reveille JD, Guerra S, Teruel M, Carmona FD, Gregersen PK, Lee AT, López-Isac E, Ochoa E, Carreira P, Simeón CP, Castellví I, González-Gay MÁ, Group T, Ortego-Centeno N, Ríos R, Callejas J, Navarrete N, Portales R, Camps M, Fernández-Nebro A, González-Escribano M, Sánchez-Román J, García-Hernández F, Castillo M, Aguirre M, Gómez-Gracia I, Fernández-Gutiérrez B, Rodríguez-Rodríguez L, Vicente E, Andreu J, de Castro M, de la Peña P, López-Longo F, Martínez L, Fonollosa V, Espinosa G, Tolosa C, Pros A, Carballeira M, Narváez F, Rivas M, Santamaría V, Díaz B, Trapiella L, del Carmen Freire M, Sousa A, Egurbide M, Mateo P, Sáez-Comet L, Díaz F, Hernández V, Beltrán E, Román-Ivorra J, Grau E, Sancho J, García F, Oreiro N, Sueiro L, Zhernakova A, Padyukov L, Alarcón-Riquelme M, Wijmenga C, Brown M, Beretta L, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler J, Voskuyl A, Schuerwegh A, Hesselstrand R, Nordin A, Airó P, Lunardi C, Shiels P, van Laar J, Herrick A, Worthington J, Denton C, Wigley F, Hummers L, Varga J, Hinchcliff M, Baron M, Hudson M, Pope J, Furst D, Khanna D, Phillips K, Schiopu E, Segal B, Molitor J, Silver R, Steen V, Simms R, Lafyatis R, Fessler B, Frech T, AlKassab F, Docherty P, Kaminska E, Khalidi N, Jones H, Markland J, Robinson D, Broen J, Radstake T, Fonseca C, Koeleman B, Martin J. Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal Of Human Genetics 2014, 94: 47-61. PMID: 24387989, PMCID: PMC3882906, DOI: 10.1016/j.ajhg.2013.12.002.
• Early Growth Response 3 (Egr-3) Is Induced by Transforming Growth Factor-β and Regulates Fibrogenic ResponsesFang F, Shangguan AJ, Kelly K, Wei J, Gruner K, Ye B, Wang W, Bhattacharyya S, Hinchcliff ME, Tourtellotte WG, Varga J. Early Growth Response 3 (Egr-3) Is Induced by Transforming Growth Factor-β and Regulates Fibrogenic Responses. American Journal Of Pathology 2013, 183: 1197-1208. PMID: 23906810, PMCID: PMC3791870, DOI: 10.1016/j.ajpath.2013.06.016.
• Treatment of early diffuse systemic sclerosis skin disease.Frech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, Hinchcliff ME, Steen V, Khanna D, Kayser C, Domsic RT. Treatment of early diffuse systemic sclerosis skin disease. Clinical And Experimental Rheumatology 2013, 31: 166-71. PMID: 23910619, PMCID: PMC3889109.
• A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responsesWei J, Zhu H, Komura K, Lord G, Tomcik M, Wang W, Doniparthi S, Tamaki Z, Hinchcliff M, Distler JH, Varga J. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Annals Of The Rheumatic Diseases 2013, 73: 446. PMID: 23515440, PMCID: PMC4028127, DOI: 10.1136/annrheumdis-2012-202716.
• Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic SclerosisHinchcliff M, Huang CC, Wood TA, Mahoney J, Martyanov V, Bhattacharyya S, Tamaki Z, Lee J, Carns M, Podlusky S, Sirajuddin A, Shah SJ, Chang RW, Lafyatis R, Varga J, Whitfield ML. Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. Journal Of Investigative Dermatology 2013, 133: 1979-1989. PMID: 23677167, PMCID: PMC3714324, DOI: 10.1038/jid.2013.130.
• Assessment of diffuse myocardial fibrosis in systemic sclerosis by cardiac magnetic resonance imagingLee D, Sarnari R, Benefield B, Aquino A, Carr J, Varga J, Hinchcliff M, Wu E, Shah S. Assessment of diffuse myocardial fibrosis in systemic sclerosis by cardiac magnetic resonance imaging. Journal Of Cardiovascular Magnetic Resonance 2013, 15: e121. PMCID: PMC3559286, DOI: 10.1186/1532-429x-15-s1-e121.
• how to detect SSc-PAHDeveloped peer-reviewed on-line course to train rheumatologists how to detect SSc-PAH
• The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic SclerosisPeljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, Carns M, Schwarz M, Varga J, Schwartz DA. The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis. CHEST Journal 2012, 142: 1584-1588. PMID: 22576636, PMCID: PMC3515031, DOI: 10.1378/chest.12-0110.
• Text data extraction for a prospective, research-focused data mart: implementation and validationHinchcliff M, Just E, Podlusky S, Varga J, Chang RW, Kibbe WA. Text data extraction for a prospective, research-focused data mart: implementation and validation. BMC Medical Informatics And Decision Making 2012, 12: 106. PMID: 22970696, PMCID: PMC3537747, DOI: 10.1186/1472-6947-12-106.
• Wnt/β‐catenin signaling is hyperactivated in systemic sclerosis and induces Smad‐dependent fibrotic responses in mesenchymal cellsWei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, Gottardi CJ, Atit R, Whitfield ML, Varga J. Wnt/β‐catenin signaling is hyperactivated in systemic sclerosis and induces Smad‐dependent fibrotic responses in mesenchymal cells. Arthritis & Rheumatism 2012, 64: 2734-2745. PMID: 22328118, PMCID: PMC3553791, DOI: 10.1002/art.34424.
• Fibrosis in systemic sclerosis: common and unique pathobiologyBhattacharyya S, Wei J, Tourtellotte WG, Hinchcliff M, Gottardi CG, Varga J. Fibrosis in systemic sclerosis: common and unique pathobiology. Fibrogenesis & Tissue Repair 2012, 5: s18. PMID: 23259815, PMCID: PMC3368774, DOI: 10.1186/1755-1536-5-s1-s18.
• Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis.Hinchcliff M, Desai CS, Varga J, Shah SJ. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clinical And Experimental Rheumatology 2012, 30: s30-7. PMID: 22338601, PMCID: PMC3507505.
• Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.Hinchcliff M, Huang CC, Ishida W, Fang F, Lee J, Jafari N, Wilkes M, Bhattacharyya S, Leof E, Varga J. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clinical And Experimental Rheumatology 2012, 30: s86-96. PMID: 22691216, PMCID: PMC3860597.
• ReplyHinchcliff M, Beaumont J, Varga J, Chung A, Podlusky S, Carns M, Chang R, Cella D, Thavarajah K. Reply. Arthritis Care & Research 2012, 64: 943-944. DOI: 10.1002/acr.21575.
• Risk Variant For ILD Does Not Influence Systemic Sclerosis (SSc) Associated ILDPeljto A, Steele M, Fingerlin T, Hinchcliff M, Carns M, Schwarz M, Varga J, Schwartz D. Risk Variant For ILD Does Not Influence Systemic Sclerosis (SSc) Associated ILD. 2012, a6605-a6605. DOI: 10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6605.
• Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML, Sodin-Semrl S, Varga J. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Research & Therapy 2012, 14: r102. PMID: 22548780, PMCID: PMC3446479, DOI: 10.1186/ar3827.
• Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registryBae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, Domsic R, Fischer A, Frech T, Goldberg A, Hinchcliff M, Hsu V, Hummers L, Schiopu E, Mayes MD, McLaughlin V, Molitor J, Naz N, Furst DE, Maranian P, Steen V, Khanna D. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Annals Of The Rheumatic Diseases 2012, 71: 1335. PMID: 22307943, PMCID: PMC3398226, DOI: 10.1136/annrheumdis-2011-200546.
• Measurement of extracellular volume fraction by cardiac magnetic resonance imaging detects diffuse myocardial fibrosis in systemic sclerosisLee D, Sarnari R, Aquino A, Izquierdo-Gomez M, Benefield B, Hinchcliff M, Varga J, Podlusky S, Carr M, Kino A, Carr J, Wu E, Shah S. Measurement of extracellular volume fraction by cardiac magnetic resonance imaging detects diffuse myocardial fibrosis in systemic sclerosis. Journal Of Cardiovascular Magnetic Resonance 2012, 14: o28. PMCID: PMC3304819, DOI: 10.1186/1532-429x-14-s1-o28.
• Generic Patient –Reported Outcome Instruments In Systemic Sclerosis: Patient-Reported Outcomes Information System (PROMIS) and Functional Assessment of Chronic Illness Therapy (FACIT). Book Chapter in Scleroderma: From Pathogenesis to Comprehensive Management.Hinchcliff M, Cella D. Editors Varga J, Denton C, Wigley F. Invited review and peer-reviewed.
• Patient-Reported OutcomesHinchcliff M, Cella D. Patient-Reported Outcomes. 2011, 673-678. DOI: 10.1007/978-1-4419-5774-0_56.
• Post‐epidemic eosinophilia–myalgia syndrome associated with L‐tryptophanAllen JA, Peterson A, Sufit R, Hinchcliff ME, Mahoney JM, Wood TA, Miller FW, Whitfield ML, Varga J. Post‐epidemic eosinophilia–myalgia syndrome associated with L‐tryptophan. Arthritis & Rheumatism 2011, 63: 3633-3639. PMID: 21702023, PMCID: PMC3848710, DOI: 10.1002/art.30514.
• Validity of two new patient‐reported outcome measures in systemic sclerosis: Patient‐reported outcomes measurement information system 29‐item health profile and functional assessment of chronic illness therapy–dyspnea short formHinchcliff M, Beaumont JL, Thavarajah K, Varga J, Chung A, Podlusky S, Carns M, Chang RW, Cella D. Validity of two new patient‐reported outcome measures in systemic sclerosis: Patient‐reported outcomes measurement information system 29‐item health profile and functional assessment of chronic illness therapy–dyspnea short form. Arthritis Care & Research 2011, 63: 1620-1628. PMID: 22034123, PMCID: PMC3205420, DOI: 10.1002/acr.20591.
• Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polypsTan BK, Li QZ, Suh L, Kato A, Conley DB, Chandra RK, Zhou J, Norton J, Carter R, Hinchcliff M, Harris K, Peters A, Grammer LC, Kern RC, Mohan C, Schleimer RP. Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps. Journal Of Allergy And Clinical Immunology 2011, 128: 1198-1206.e1. PMID: 21996343, PMCID: PMC3384688, DOI: 10.1016/j.jaci.2011.08.037.
• Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study PopulationHinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population. The Journal Of Rheumatology 2011, 38: 2172-2179. PMID: 21844142, PMCID: PMC3230328, DOI: 10.3899/jrheum.101243.
• Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association StrategyGorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, Diaz-Gallo LM, Broen JC, Vonk MC, Simeon CP, Alizadeh BZ, Coenen MJ, Voskuyl AE, Schuerwegh AJ, van Riel PL, Vanthuyne M, van 't Slot R, Italiaander A, Ophoff RA, Hunzelmann N, Fonollosa V, Ortego-Centeno N, González-Gay MA, García-Hernández FJ, González-Escribano MF, Airo P, van Laar J, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels PG, Westhovens R, Kreuter A, de Baere E, Witte T, Padyukov L, Nordin A, Scorza R, Lunardi C, Lie BA, Hoffmann-Vold AM, Palm Ø, García de la Peña P, Carreira P, , Varga J, Hinchcliff M, Lee AT, Gourh P, Amos CI, Wigley FM, Hummers LK, Hummers J, Nelson J, Riemekasten G, Herrick A, Beretta L, Fonseca C, Denton C, Gregersen P, Agarwal S, Assassi S, Tan F, Arnett F, Radstake T, Mayes M, Martin J. Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLOS Genetics 2011, 7: e1002178. PMID: 21779181, PMCID: PMC3136437, DOI: 10.1371/journal.pgen.1002178.
• Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma?Wei J, Melichian D, Komura K, Hinchcliff M, Lam AP, Lafyatis R, Gottardi CJ, MacDougald OA, Varga J. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma? Arthritis & Rheumatism 2011, 63: 1707-1717. PMID: 21370225, PMCID: PMC3124699, DOI: 10.1002/art.30312.
• Managing Systemic Sclerosis and Its Complications.Hinchcliff M, Varga J. The Journal of Musculoskeletal Medicine. October 2011, pp 380-387.
• Identification of novel genetic markers associated with the clinical phenotypes of systemic sclerosis through a genome wide association strategyGorlova O, Martin J, Rueda B, Koeleman B, Ying J, Teruel M, Diaz-Gallo L, Broen J, Vonk M, Simeon C, Alizadeh B, Coenen M, Voskuyl A, Schuerwegh A, van Riel P, Vanthuyne M, van ‘t Slot R, Italiaander A, Ophoff R, Hunzelmann N, Fonollosa V, Ortego-Centeno N, González-Gay M, García-Hernández F, González-Escribano M, Airo P, van Laar J, Worthington J, Hesselstrand R, Smith V, De Keyser F, Houssiau F, Chee M, Madhok R, Shiels P, Westhovens R, Kreuter A, de Baere E, Witte T, Padyukov L, Nordin A, Scorza R, Lunardi C, Lie B, Hoffmann-Vold A, García de la Peña P, Carreira P, Varga J, Hinchcliff M, Lee A, Gourh P, Amos C, Riemekasten G, Herrick A, Beretta L, Fonseca C, Denton C, Gregersen P, Agarwal S, Assassi S, Tan F, Arnett F, Radstake T, Mayes M, Martin J. Identification of novel genetic markers associated with the clinical phenotypes of systemic sclerosis through a genome wide association strategy. Journal Of Translational Medicine 2010, 8: o1. PMCID: PMC3007743, DOI: 10.1186/1479-5876-8-s1-o1.
• Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locusRadstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ, Broen JC, van Riel PL, van 't Slot R, Italiaander A, Ophoff RA, Riemekasten G, Hunzelmann N, Simeon CP, Ortego-Centeno N, González-Gay MA, González-Escribano MF, Airo P, van Laar J, Herrick A, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee M, Madhok R, Shiels P, Westhovens R, Kreuter A, Kiener H, de Baere E, Witte T, Padykov L, Klareskog L, Beretta L, Scorza R, Lie B, Hoffmann-Vold A, Carreira P, Varga J, Hinchcliff M, Gregersen P, Lee A, Ying J, Han Y, Weng S, Amos C, Wigley F, Hummers L, Nelson J, Agarwal S, Assassi S, Gourh P, Tan F, Koeleman B, Arnett F, Martin J, Mayes M. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics 2010, 42: 426-429. PMID: 20383147, PMCID: PMC2861917, DOI: 10.1038/ng.565.
• Evidence of Airflow Obstruction in Systemic Sclerosis.Thavarajah K, Hinchcliff M, Patel S, Varga J, D'Amico J. Evidence of Airflow Obstruction in Systemic Sclerosis. 2009, a4495. DOI: 10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4495.
• A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylateBhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, Leof E, Varga J. A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009, 28: 1285-1297. PMID: 19151753, PMCID: PMC4006376, DOI: 10.1038/onc.2008.479.
• Systemic sclerosis/scleroderma: a treatable multisystem disease.Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. American Family Physician 2008, 78: 961-8. PMID: 18953973.
• Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-β responsivenessMori Y, Hinchcliff M, Wu M, Warner-Blankenship M, Lyons K, Varga J. Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-β responsiveness. Experimental Cell Research 2007, 314: 1094-1104. PMID: 18201696, PMCID: PMC3963386, DOI: 10.1016/j.yexcr.2007.12.010.
• Novel paradigm for treating vasculopathy in systemic sclerosis: Vascular progenitor cells and statinsHinchcliff M, Varga J. Novel paradigm for treating vasculopathy in systemic sclerosis: Vascular progenitor cells and statins. Current Rheumatology Reports 2007, 9: 1-3. PMID: 17437659, DOI: 10.1007/s11926-007-0014-1.
• Managing Systemic Sclerosis and its Complications.Hinchcliff M, Varga J. The Journal of Musculoskeletal Medicine, October 2007
• Severe reversible left ventricular dysfunction associated with multiple cardiac myxomata.Kuźniar TJ, Hinchcliff M, Zunamon A, Balagani R, Enzler M, Mandzij R. Severe reversible left ventricular dysfunction associated with multiple cardiac myxomata. Wiadomosci Lekarskie (Warsaw, Poland : 1960) 2007, 60: 291-3. PMID: 17966897.
• Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapyHinchcliff M, Varga J. Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy. Expert Review Of Clinical Immunology 2007, 3: 11-15. PMID: 20476946, DOI: 10.1586/1744666x.3.1.11.